IRIS
CAVAZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.937
AS - Asia 5.330
EU - Europa 5.114
SA - Sud America 888
AF - Africa 297
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 18.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.813
SG - Singapore 2.193
CN - Cina 1.809
IT - Italia 1.044
FI - Finlandia 817
IE - Irlanda 784
BR - Brasile 727
SE - Svezia 698
DE - Germania 523
HK - Hong Kong 422
UA - Ucraina 339
VN - Vietnam 325
NL - Olanda 216
ZA - Sudafrica 175
TR - Turchia 155
GB - Regno Unito 141
RU - Federazione Russa 124
IN - India 123
FR - Francia 113
CA - Canada 84
AT - Austria 83
BE - Belgio 76
CI - Costa d'Avorio 66
AR - Argentina 57
PL - Polonia 42
BD - Bangladesh 40
JP - Giappone 35
EC - Ecuador 34
ES - Italia 30
ID - Indonesia 30
MX - Messico 27
PK - Pakistan 26
IQ - Iraq 25
KR - Corea 23
CO - Colombia 22
CZ - Repubblica Ceca 21
LT - Lituania 19
MA - Marocco 15
IR - Iran 13
VE - Venezuela 13
AZ - Azerbaigian 12
JO - Giordania 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
EG - Egitto 11
KE - Kenya 10
PS - Palestinian Territory 10
CL - Cile 9
TN - Tunisia 8
PY - Paraguay 7
BO - Bolivia 6
IL - Israele 6
KG - Kirghizistan 6
LU - Lussemburgo 6
PE - Perù 6
UY - Uruguay 6
AL - Albania 5
JM - Giamaica 5
KZ - Kazakistan 5
LB - Libano 5
NP - Nepal 5
SA - Arabia Saudita 5
NZ - Nuova Zelanda 4
RO - Romania 4
SY - Repubblica araba siriana 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EU - Europa 3
HU - Ungheria 3
RS - Serbia 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
CY - Cipro 2
EE - Estonia 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
MK - Macedonia 2
OM - Oman 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
AD - Andorra 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
Totale 18.568
Salva come PNG Salva come JPEG
Città #
Singapore 1.097
Dallas 821
Dublin 784
Chandler 744
Ashburn 723
Ann Arbor 509
Santa Clara 487
Beijing 455
Hong Kong 416
Jacksonville 380
Parma 348
Dearborn 281
Boardman 225
Nanjing 179
Johannesburg 168
New York 168
Shanghai 164
Munich 163
Los Angeles 150
Princeton 135
Izmir 132
Ho Chi Minh City 116
San Mateo 113
Hefei 111
Milan 87
Bremen 86
Helsinki 84
Wilmington 84
São Paulo 74
Nanchang 72
Vienna 68
Abidjan 66
Hanoi 62
Moscow 60
Brussels 59
Buffalo 57
Shenyang 57
Kunming 56
Marseille 52
Des Moines 51
Hebei 49
Jinan 48
Chicago 43
Tianjin 43
Columbus 41
Toronto 41
Woodbridge 38
Guangzhou 37
Turku 37
Amsterdam 35
Houston 35
Modena 34
Seattle 32
Bologna 31
The Dalles 31
Changsha 30
Warsaw 30
Frankfurt am Main 29
Jiaxing 29
Tokyo 28
Pune 27
London 25
Rio de Janeiro 25
Redmond 22
Stockholm 22
Jakarta 21
Council Bluffs 20
Wayne 20
Brooklyn 19
Denver 19
Norwalk 19
Nuremberg 19
Reggio Emilia 19
Seoul 19
Montreal 17
Poplar 17
Rome 17
Augusta 16
Haiphong 16
Phoenix 16
Quito 16
Zhengzhou 16
Brasília 15
Chennai 15
Fremont 15
Manchester 15
Belo Horizonte 14
Leawood 14
San Francisco 14
Boston 13
Campinas 13
Da Nang 13
Hangzhou 13
Amman 12
Düsseldorf 12
Wuhan 12
Atlanta 11
Baku 11
Fuzhou 11
Grafing 11
Totale 11.326
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 310
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 219
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 205
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 204
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 201
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 189
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 185
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 179
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 177
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 163
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 162
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 162
Characterization of gefitinib uptake in NSCLC cell lines 161
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 161
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 161
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 159
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 154
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 153
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 151
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 151
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 150
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 148
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 147
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 147
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 146
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 146
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 146
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 145
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 144
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 144
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 143
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 143
5-benzylidene-hydantoins as new inhibitors of cell proliferation 142
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 142
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 139
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 139
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 138
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 138
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 135
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 134
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 134
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 133
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 133
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 132
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 131
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 131
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 130
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 129
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 128
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 128
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 128
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 128
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 127
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 126
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 126
Mannich base derivatives as novel EGFR irreversible inhibitors 124
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 123
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 121
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 121
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 118
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 118
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 116
Biological hallmarks and new therapeutic approaches for the treatment of pdac 116
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 115
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 112
Irreversible EGFR inhibitor compounds with antiproliferative activity 112
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 112
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 112
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 112
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 111
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 110
Hypertonic stress and amino acid deprivation both increase expression of mRNA for amino acid transport system A 110
Antibacterial and antitumor activity of tetracyclic fluoroquinolones with pyrido[2,3-a]carbazole structure 109
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 109
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 108
New imidazo[2,1-b][1,3,4]thiadiazole aerivatives anhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma 108
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 107
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 106
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 106
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 105
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 103
Induzione di osmotolleranza in cellule endoteliali derivate da arteria polmonare 102
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 102
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 102
Intrapleural application of polymeric films containing cisplatin and pemetrexed in a rat tumour model of malignant pleural mesothelioma 102
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 101
Totale 13.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021660 0 0 0 0 0 38 107 51 172 38 205 49
2021/2022727 49 30 34 48 13 13 100 67 44 59 38 232
2022/20233.019 284 313 209 200 275 341 27 251 955 17 114 33
2023/20241.275 66 96 48 56 104 298 94 82 44 67 125 195
2024/20254.226 133 210 271 313 409 462 247 176 542 355 389 719
2025/20264.989 782 871 1.175 823 1.249 89 0 0 0 0 0 0
Totale 18.833